Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Marjorie Z Imperial^#¹, Payam Nahid^#¹, Patrick P J Phillips¹, Geraint R Davies², Katherine Fielding³, Debra Hanna^{4

5}, David Hermann⁵, Robert S Wallis⁶, John L Johnson^{7

8}, Christian Lienhardt^{9

10}, Rada M Savic¹¹

Affiliations

¹ University of California, San Francisco, San Francisco, CA, USA.
² University of Liverpool, Liverpool, UK.
³ London School of Hygiene and Tropical Medicine, London, UK.
⁴ Critical Path Institute, Tucson, AZ, USA.
⁵ Bill and Melinda Gates Foundation, Seattle, WA, USA.
⁶ Aurum Institute and ACT4TB/HIV, Johannesburg, South Africa.
⁷ Case Western Reserve University, Cleveland, OH, USA.
⁸ University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
⁹ Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
¹⁰ Unité Mixte Internationale TransVIHMI (UMI 233 IRD-U1175 INSERM-Université de Montpellier), Institut de Recherche pour le Développement (IRD), Montpellier, France.
¹¹ University of California, San Francisco, San Francisco, CA, USA. rada.savic@ucsf.edu.

^# Contributed equally.

PMID: 30429542
PMCID: PMC7608289
DOI: 10.1038/s41591-018-0294-1

Published Erratum

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Marjorie Z Imperial et al. Nat Med. 2019 Jan.

. 2019 Jan;25(1):190.

doi: 10.1038/s41591-018-0294-1.

Authors

Affiliations

¹ University of California, San Francisco, San Francisco, CA, USA.
² University of Liverpool, Liverpool, UK.
³ London School of Hygiene and Tropical Medicine, London, UK.
⁴ Critical Path Institute, Tucson, AZ, USA.
⁵ Bill and Melinda Gates Foundation, Seattle, WA, USA.
⁶ Aurum Institute and ACT4TB/HIV, Johannesburg, South Africa.
⁷ Case Western Reserve University, Cleveland, OH, USA.
⁸ University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
⁹ Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland.
¹⁰ Unité Mixte Internationale TransVIHMI (UMI 233 IRD-U1175 INSERM-Université de Montpellier), Institut de Recherche pour le Développement (IRD), Montpellier, France.
¹¹ University of California, San Francisco, San Francisco, CA, USA. rada.savic@ucsf.edu.

^# Contributed equally.

PMID: 30429542
PMCID: PMC7608289
DOI: 10.1038/s41591-018-0294-1

Abstract

The version of this article originally published was not open access. This article should have been open access. The error has been fixed, and the article is now open access.

PubMed Disclaimer

Erratum for

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.
Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. Imperial MZ, et al. Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5. Nat Med. 2018. PMID: 30397355 Free PMC article. Clinical Trial.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Affiliations

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis

Authors

Affiliations

Abstract

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources